European Urology
2008-11-01
Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Stéphane Oudard
Index: Eur. Urol. 54(5) , 1094-6, (2008)
Full Text: HTML
Abstract
Related Articles:
Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.
2014-01-01
[Biol. Pharm. Bull. 37(9) , 1550-4, (2014)]
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
2008-05-01
[Eur. J. Cancer 44(7) , 912-20, (2008)]
Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.
2009-01-01
[Clin. Cancer Res. 15(1) , 238-46, (2009)]
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment
2010-01-01
[Eur. J. Cancer 46 , 3022-36, (2010)]
Novel therapeutic strategies in development for prostate cancer.
2008-01-01
[Expert Opin. Investig. Drugs 17(1) , 13-22, (2008)]